Acute Renal Failure under Dasatinib Therapy

作者：Ozkurt Sultan; Temiz Gokhan^*; Acikalin Mustafa Fuat; Soydan Mehmet

来源：Renal Failure, 2010, 32(1): 147-149.

DOI：10.3109/08860220903391226

• acute renal failure
• chronic myeloid leukemia
• tyrosine kinase inhibitors
• dasatinib

Dasatinib is a second-generation tyrosine kinase inhibitor that is approved for the treatment of imatinib-resistant or imatinib-intolerant chronic myeloid leukemia. It has a 325 times stronger in vitro activity against to native BCR-ABL when comparing with imatinib. Little is known about the effects of dasatinib on renal function. A literature review revealed only one case with imatinib-resistant chronic myeloid leukemia that developed renal failure after being placed on dasatinib therapy. Here we report a patient with imatinib-resistant chronic myeloid leukemia who developed gastroenteritis and acute renal failure after a short time from the initiation of dasatinib therapy. After dasatinib interruption, these side effects resolved completely in days. In summary, dasatinib is a potent drug in the treatment of chronic myeloid leukemia, but close clinical monitoring and the timely interruption of the therapy in patients who developed acute renal failure are warranted.

• 出版日期2010